Show simple item record

dc.contributor.authorHsiao, Chao-Pin
dc.contributor.authorChen, Mei-Kuang
dc.contributor.authorDaly, Barbara
dc.contributor.authorHoppel, Charles
dc.date.accessioned2019-05-22T16:43:57Z
dc.date.available2019-05-22T16:43:57Z
dc.date.issued2018-01-01
dc.identifier.citationHsiao, C. P., Chen, M. K., Daly, B., & Hoppel, C. (2018). integrated mitochondrial function and cancer-related fatigue in men with prostate cancer undergoing radiation therapy. Cancer management and research, 10, 6367.en_US
dc.identifier.issn1179-1322
dc.identifier.pmid30568498
dc.identifier.doi10.2147/CMAR.S185706
dc.identifier.urihttp://hdl.handle.net/10150/632361
dc.description.abstractIntroduction: Fatigue experienced by cancer patients is one of the most common symptoms with the greatest adverse effect on quality of life, but arguably the least understood. The purpose of this study was to explore changes in integrated mitochondrial function and fatigue in non-metastatic prostate cancer patients receiving localized radiation therapy (XRT). Materials and methods: We proposed a mitochondria' bioenergetics mechanism of radiation-induced fatigue linking impaired oxidative phosphorylation (OXPIIOS) through complex III and decreased adenosine triphosphate (ATP) production as consequences of XRT. Integrated mitochondria' function was measured as mitochondria' OXPHOS from patients' peripheral blood mononuclear cells. Fatigue was measured using the revised Piper Fatigue Scale. Data were collected before (day 0) and at day 21 of XRT. Results: At day 21 of XRT, fatigue symptom intensified in 15 prostate cancer patients (P<0.05). Mitochondrial OXPHOS complex III-linked and uncoupled complex III rates were significantly decreased in mononuclear cells at day 21 during XRT compared to that before XRT (P<0.05). Additionally, increased fatigue appeared to be associated with decreased OXPHOS complex Ill-linked respiration in patients undergoing XRT. Conclusion: Fatigue was associated with OXPHOS complex III-linked oxidation and a defect in oxidation starting at complex III in mononuclear cell mitochondria was revealed at day 21 of XRT in 15 prostate cancer patients. Complex III is a potential target for pharmacological and, in particular, nutraceutical interventions, eg, Q10, for design of interventions for CRF.en_US
dc.description.sponsorshipNational Institute of Nursing Research, National Institutes of Health [K01 NR015246]; Oncology Nursing Society Foundation, Pittsburg, PA [RES125833]; Center for Mitochondrial Disease, Case Western Reserve Universityen_US
dc.language.isoenen_US
dc.publisherDOVE MEDICAL PRESS LTDen_US
dc.relation.urlhttps://www.dovepress.com/integrated-mitochondrial-function-and-cancer-related-fatigue-in-men-wi-peer-reviewed-fulltext-article-CMARen_US
dc.rights© 2018 Hsiao et al. This work is published and licensed by Dove Medical Press Limited.en_US
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.subjectcancer-related fatigueen_US
dc.subjectintegrated mitochondrial functionen_US
dc.subjectoxidative phosphorylationen_US
dc.subjectprostate canceren_US
dc.subjectradiation therapyen_US
dc.titleIntegrated mitochondrial function and cancer-related fatigue in men with prostate cancer undergoing radiation therapyen_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Dept Psycholen_US
dc.identifier.journalCANCER MANAGEMENT AND RESEARCHen_US
dc.description.noteOpen access journalen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleCancer management and research
refterms.dateFOA2019-05-22T16:43:58Z


Files in this item

Thumbnail
Name:
cmar-185706-integrated-mitocho ...
Size:
754.4Kb
Format:
PDF
Description:
Final Published version

This item appears in the following Collection(s)

Show simple item record